We believe that microarchitectural
mitigation of our Prime variants will require new considerations.
Osteoporosis is a bone disease characterized by low bone mass and microarchitectural
deterioration of bone tissue leading to enhanced bone fragility and a consequent increase in fracture risk (37).
15] examined the microstructural model of the vertebra of the lumbar region to investigate the microarchitectural
changes effects of the osteoporotic trabecular bone on the vertebral instability.
These include general factors that relate to aging and sex steroid deficiency, as well as specific risk factors such as use of glucocorticoids (which cause decreased bone formation and bone loss), reduced bone quality, and disruption of microarchitectural
Notably, distinction must be drawn between the ability of BTMs to predict bone loss, as discussed above, with their ability to predict fracture risk, as patients can have markedly differing fracture risks at a given overall level of bone mass due to variation in demographic, clinical, and bone microarchitectural
World Health Organisation (WHO) defines osteoporosis as a disease that is characterized by low bone mass and microarchitectural
destruction of bone tissue, leading to bone fragility and increased risk of fracture.
changes at the distal radius and tibia in postmenopausal women using HR-pQCT.
20] Osteoporosis is defined as a metabolic bone disease 'characterised by low bone mass and microarchitectural
deterioration of bone tissue leading to enhanced bone fragility and a consequent increase in fracture risk'.
Postmenopausal osteoporosis is a disease characterized by bone loss and microarchitectural
deterioration leading to bone fragility and an increased risk of fracture.
parameters of proximal femoral spongiosa were measured by Micro-CT machine.
Exploiting application/system- dependent ambient temperature for accurate microarchitectural
simulation," IEEE Transactions on Computers, vol.
Both of KN and EV reversed the above mentioned indices, preventing OVX-induced trabecular bone microarchitectural
deterioration and improving the bone loss after 12 weeks administration.